BALPHARMA vs PFIZER: Stock Comparison
PFIZER is the larger company by market capitalisation. PFIZER shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALPHARMA leads 1; PFIZER leads 8 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALPHARMA | PFIZER |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BALPHARMA | PFIZER |
|---|---|---|
| Live Price | ₹106.79 | ₹3,688.9 |
| Day Change | 0.99% | -1.75% |
| Volume | 25,522 | 29,568 |
| 52-Week High | ₹124.6 | ₹5,446 |
| 52-Week Low | ₹60 | ₹3,731 |
| Distance from 52W High | -14.29% | -32.26% |
Valuation
| Metric | BALPHARMA | PFIZER |
|---|---|---|
| Market Cap | ₹134 Cr | ₹16,817 Cr |
| P/E Ratio | — | 22.87x |
| P/B Ratio | — | 4x |
| EPS | ₹0.71 | ₹44.7 |
| Book Value | ₹51.66 | ₹918.71 |
| Dividend Yield | 1.36% | 1.99% |
Growth
| Metric | BALPHARMA | PFIZER |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.7% | 6.3% |
| EPS Growth (TTM YoY) | -33.5% | -39.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BALPHARMA | PFIZER |
|---|---|---|
| ROE | 6.49% | 17.19% |
| ROCE | 9.07% | 17.78% |
| Net Margin | 2.02% | 28.67% |
| Operating Margin | 7.46% | 39.1% |
| Debt to Equity | 1.48x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BALPHARMA | PFIZER |
|---|---|---|
| Promoter Holding | 46.74% | 63.92% |
| FII Holding | 0.28%▲ 0.13 pp | 1.63%▼ 0.02 pp |
| DII Holding | 0% | 17.52%▼ 0.28 pp |
| Public Holding | 48.87%▼ 0.12 pp | 16.92%▲ 0.29 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and PFIZER.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.